Source: FierceBiotech More than 5 years after The Medicines Company ($MDCO) bagged Targanta and its troubled antibiotic oritavancin for the bargain basement rate of $42 million plus potential bonus payments, the biotech has finally nailed down an elusive FDA approval of the product for skin infections caused by Gram-positive bacteria,…...